HIV vaccine trial is halted

  • National Institutes of Health Newsroom
  • NIH
  • 2 Feb 2020

  • curated by Liz Scherer
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • National Institute of Allergy and Infectious Diseases (NIAID) announced that it has halted the Uhambo (HVTN 702) clinical trial because of ineffectiveness of the trial HIV vaccine.

Why this matters

  • NIAID emphasized that there was no concern over HVTN 702 vaccine safety, which was closely monitored throughout the trial by an independent data and safety monitoring board (DSMB).
    • Participant monitoring continues.
  • Additional vaccine regimens (novel mosaic vaccine regimen, effectiveness of broadly neutralizing antibodies) are involved in late-stage investigational trials.

Key points

  • Starting in 2016, HVTN enrolled and randomized 5407 sexually active South African HIV-negative adults (ages, 18-35 years) across 14 sites to investigational vaccine or placebo injections (6 injections over 18 months) plus preventative HIV standard of care (including oral preexposure prophylaxis).
  • HVTN 702 vaccine regimen was modified to be specific for HIV subtype Clade C:
    • Canarypox vector-based vaccine (ALVAC-HIV).
    • 2-component, adjuvanted gp120 protein subunit vaccine.
    • Booster shots were administered at 1 year, 19 months to prolong previously observed protective effect.
  • A January 23 DSMB interim analysis of 2694 vaccine recipients vs 2689 placebo recipients demonstrated no significant efficacy based on the primary objective (number of participants diagnosed with HIV after >60% had been in study for >18 months):
    • 129 HIV infections occurred among vaccine recipients compared with 123 among those receiving placebo.